Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Open-Label Study of UM171-Expanded Cord Blood Transplantation in Patients With High and Very High Risk Acute Leukemia/Myelodysplasia

Next Previous
Trial Profile

A Phase II Open-Label Study of UM171-Expanded Cord Blood Transplantation in Patients With High and Very High Risk Acute Leukemia/Myelodysplasia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allogeneic umbilical cord-derived CD34-cells unexpanded/dorocubicel (Primary) ; Cyclophosphamide; Fludarabine; MMF; Tacrolimus; Thiotepa
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ExCellThera

Most Recent Events

  • 10 Mar 2026 Results published in the Media Release
  • 10 Mar 2026 According to an ExCellThera media release, Topline results will be presented on March 23, 2026 at the 52nd EBMT Annual Meeting in Madrid, Spain.
  • 10 Dec 2024 Results examining the outcome of patients with poor outcome TP53 or EVI1 anomalies who were transplanted with a single UM171 CBT during the course of phase I-II(n=1) and phase II(n=9) trial, presented at the 66th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top